​

Guardant Health (GH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GH Stock Forecast

Guardant Health (GH) stock forecast, based on 30 Wall Street analysts, predicts a 12-month average price target of $133.14, with a high of $175.00 and a low of $110.00. This represents a 49.75% increase from the last price of $88.91.

- $40 $80 $120 $160 $200 High: $175 Avg: $133.14 Low: $110 Last Closed Price: $88.91

GH Stock Rating

Guardant Health stock's rating consensus is Buy, based on 30 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 28 Buy (93.33%), 1 Hold (3.33%), 1 Sell (3.33%), and 0 Strong Sell (0.00%).

Buy
Total 30 1 1 28 Strong Sell Sell Hold Buy Strong Buy

GH Price Target Upside V Benchmarks

TypeNameUpside
StockGuardant Health49.75%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks32.52%

Price Target Trends

1M3M12M
# Anlaysts11135
Avg Price Target$115.00$132.18$112.49
Last Closing Price$88.91$88.91$88.91
Upside/Downside29.34%48.67%26.52%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 265162--23
Mar, 265172--24
Feb, 2651611-23
Jan, 26517--123
Dec, 25517-1-23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 14, 2026Luke SergottBarclays$115.00$82.2139.89%29.34%
Feb 24, 2026Piper Sandler$130.00$94.4237.68%46.22%
Feb 23, 2026Raymond James$129.00$97.4932.32%45.09%
Feb 20, 2026Evercore ISI$110.00$106.842.96%23.72%
Feb 20, 2026BTIG$145.00$106.3836.30%63.09%
Feb 20, 2026Stifel Nicolaus$130.00$106.3822.20%46.22%
Feb 20, 2026Canaccord Genuity$135.00$106.3826.90%51.84%
Feb 20, 2026Barclays$130.00$106.3822.20%46.22%
Feb 17, 2026Catherine SchulteRobert W. Baird$120.00$104.8514.45%34.97%
Jan 30, 2026UBS$175.00$111.0057.66%96.83%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 14, 2026BarclaysOverweightOverweighthold
Feb 24, 2026Piper SandlerOverweightOverweighthold
Feb 23, 2026Raymond JamesOutperformOutperformhold
Feb 20, 2026Cowen & Co.BuyBuyhold
Feb 20, 2026BTIGBuyBuyhold
Feb 20, 2026CitigroupBuyBuyhold
Feb 20, 2026BarclaysOverweightOverweighthold
Jan 30, 2026UBSBuyBuyhold
Jan 26, 2026GuggenheimBuyBuyhold
Jan 07, 2026Cowen & Co.BuyBuyhold

Financial Forecast

EPS Forecast

$-7 $-6 $-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.80$-6.41$-4.28$-3.56$-3.32---
Avg Forecast$-4.26$-6.45$-3.58$-3.41$-2.90$-2.46$-2.32$-2.13
High Forecast$-4.11$-6.26$-3.49$-3.32$-2.26$-1.18$-0.24$-2.04
Low Forecast$-4.36$-6.80$-3.68$-3.50$-3.73$-2.99$-3.72$-2.29
Surprise %-10.80%-0.62%19.55%4.40%14.48%---

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$373.65M$449.54M$563.95M$739.02M$982.02M---
Avg Forecast$364.29M$446.54M$558.07M$729.04M$846.27M$1.02B$1.23B$1.46B
High Forecast$370.66M$464.85M$589.10M$729.24M$868.09M$1.02B$1.24B$1.54B
Low Forecast$354.33M$435.97M$538.39M$728.83M$819.82M$1.02B$1.22B$1.41B
Surprise %2.57%0.67%1.05%1.37%16.04%---

Net Income Forecast

$-700M $-560M $-420M $-280M $-140M $0 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-405.67M$-654.59M$-479.45M$-436.37M$-416.28M---
Avg Forecast$-372.37M$-508.71M$-479.45M$-382.22M$-364.59M$-312.67M$-168.64M$-238.87M
High Forecast$-297.90M$-406.97M$-383.56M$-372.11M$-252.82M$-132.14M$-27.21M$-227.92M
Low Forecast$-446.85M$-610.45M$-575.34M$-392.33M$-417.56M$-334.31M$-416.51M$-256.14M
Surprise %8.94%28.68%-14.17%14.18%---

GH Forecast FAQ

Is Guardant Health stock a buy?

Guardant Health stock has a consensus rating of Buy, based on 30 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 28 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Guardant Health is a favorable investment for most analysts.

What is Guardant Health's price target?

Guardant Health's price target, set by 30 Wall Street analysts, averages $133.14 over the next 12 months. The price target range spans from $110 at the low end to $175 at the high end, suggesting a potential 49.75% change from the previous closing price of $88.91.

How does Guardant Health stock forecast compare to its benchmarks?

Guardant Health's stock forecast shows a 49.75% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (32.52%).

What is the breakdown of analyst ratings for Guardant Health over the past three months?

  • April 2026: 21.74% Strong Buy, 69.57% Buy, 8.70% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 20.83% Strong Buy, 70.83% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 21.74% Strong Buy, 69.57% Buy, 4.35% Hold, 4.35% Sell, 0% Strong Sell.

What is Guardant Health’s EPS forecast?

Guardant Health's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.46, marking a -25.90% decrease from the reported $-3.32 in 2025. Estimates for the following years are $-2.32 in 2027, and $-2.13 in 2028.

What is Guardant Health’s revenue forecast?

Guardant Health's average annual revenue forecast for its fiscal year ending in December 2026 is $1.02B, reflecting a 4.01% increase from the reported $982.02M in 2025. The forecast for 2027 is $1.23B, and $1.46B for 2028.

What is Guardant Health’s net income forecast?

Guardant Health's net income forecast for the fiscal year ending in December 2026 stands at $-313M, representing a -24.89% decrease from the reported $-416M in 2025. Projections indicate $-169M in 2027, and $-239M in 2028.